|
Depressive disorder
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Parental depression and anxiety were screened with the Patient Health Questionnaire-2 (PHQ-2) and Generalized Anxiety Disorder Scale-2 (GAD-2).
|
31222745 |
2019 |
|
Depressive disorder
|
0.070 |
Biomarker
|
disease |
BEFREE |
A random sample of 688 undergraduate university students (mean age = 20.64 ±1.88 years; 53% men) completed a survey composed of a) questions about socio-demographics, academics, lifestyle behaviors, personality type, and smartphone use-related variables; b) 26-item Smartphone Addiction Inventory (SPAI) Scale; and c) brief screeners of depression and anxiety (PHQ-2 and GAD-2), which constitute the two core DSM-IV items for major depressive disorder and generalized anxiety disorder, respectively.
|
28777828 |
2017 |
|
Depressive disorder
|
0.070 |
Biomarker
|
disease |
BEFREE |
FMR1 gene polymorphisms, dopaminergic (DAT, DRD, COMT), serotonin (5-HTTLPR, HTR1A, HTR2A), interleukins, MCR1, HCN (potassium channel), neurorregulinas, GABAergic (GABA, GAD, DBI) DBI, GABA (Gabra) receptors and GAD genes (GAD1, GAD2) appear to contribute to generate condition of depression or anxiety like.
|
25106036 |
2014 |
|
Depressive disorder
|
0.070 |
Biomarker
|
disease |
BEFREE |
Based on the rigorous standard suggested by the Quality Assessment of Diagnostic Accuracy Studies-2, a total of 1,157 participants randomly recruited from the community completed the GAD-7, GAD-2, and other anxiety and depression measures in a counter-balanced order.
|
30936840 |
2019 |
|
Depressive disorder
|
0.070 |
Biomarker
|
disease |
BEFREE |
Patients reported on perceived changes in health outcomes as measured by <i>Short-Form Health Survey</i> (<i>SF-12</i> general, mental, and physical health), <i>Perceived Stress Scale (PSS4)</i>, <i>Work Productivity and Activity Impairment Questionnaire (WPAI)</i>, <i>World Health Organization Well-Being Index (WHO-5</i>), <i>Pain Visual Analog Scale (VAS)</i>, <i>Fatigue Severity Scale (VAS; FSS)</i>, <i>Generalized Anxiety Disorder Scale (GAD2)</i>, <i>Patient Health Questionnaire</i> for depression <i>(PHQ2), Pittsburgh Sleep Quality Index (PSQI)</i> global rating of sleep quality, and the <i>Behavioral Risk Factor Surveillance System (BRFSS</i>; nutrition, exercise, and physical activity).
|
31346339 |
2019 |
|
Depressive disorder
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
There were a significant 58% increase of SCN GAD65/67-ir and a significant 169% increase of SCN GAD67-mRNA in the depression group.
|
28608287 |
2017 |
|
Depressive disorder
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Based on cut-off-scores of standardized self-report scales (PHQ-9, GAD-2), rates of depression (8.4%; 95%CI 6.90-10.30) and anxiety symptoms (7.8%; 95%CI 6.30-9.60) corresponded to those of participants without cancer.
|
31443804 |
2019 |